Pfizer announced the company’s succession plan for when Ian Read steps down as chief executive officer on January 1, 2019.
Merck & Co. Inc. Chief Executive Officer Kenneth Frazier will remain in the role beyond 2019 after scrapping a policy requiring the drugmaker’s CEOs to retire at the age of 65.
